2008 - Benazepril plus amlodipine reduced cardiovascular risk more than benazepril plus hydrochlorothiazide

Rabkin, Simon W.
May 2009
ACP Journal Club;5/19/2009, Vol. 150 Issue 5, p6
Academic Journal
The article presents a study on whether benazepril plus amlodipine prevents cardiovascular (CV) events more than benazepril plus hydrochlorothiazide (HCTZ) in high-risk patients with hypertension. The study was conducted on 11,506 patients who had hypertension and concluded that in high-risk patients with hypertension, benazepril plus amlodipine prevented cardiovascular events more than benazepril plus hydrochlorothiazide.


Related Articles

  • New benefits in statin interaction with newer antihypertensives.  // Pulse;11/19/2005, Vol. 65 Issue 45, p13 

    The article reports on the result of the sub-study conducted by Ascot in statin interaction with antihypertensive drugs.

  • Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. Sheridan, Stacey L.; Crespo, Eric // BMC Health Services Research;2008, Vol. 8, Special section p1 

    Background: Guidelines now recommend routine assessment of global coronary heart disease (CHD) risk scores. We performed a systematic review to assess whether global CHD risk scores result in clinical benefits or harms. Methods: We searched MEDLINE (1966 through June 13, 2007) for articles...

  • Journal Watch.  // Pulse;3/15/2007, Vol. 67 Issue 10, p15 

    The article reports on research findings published in various medical journals. Researchers from the Great Britain and Hong Kong, China have concluded that high doses of statins can reverse carotid atherosclerotic disease. A U.S. study has revealed the accuracy of a seven-item questionnaire to...

  • JOURNALS WATCH.  // Independent Nurse;2/16/2009, p6 

    The article offers news briefs related to medicine research. A certain study suggests that long-term statin treatment could prevent the risks of coronary heart disease (CHD). A study in the U.S. reveals that marijuana use increases the risks of testicular cancer. The study conducted by Arthritis...

  • Statins bring long-term falls in non-CVD disease. Anekwe, Lilian // Pulse;9/7/2011, Vol. 71 Issue 28, p15 

    The article reports on the result of a study conducted by researchers in Great Britain, which shows that long-term intake of statins decreases the risk of non-fatal myocardial infarction and fatal coronary heart disease (CHD).

  • Cardiovascular health knowledge and behavior in patient attendants at four tertiary care hospitals in Pakistan -- a cause for concern. Jafary, Fahim H.; Aslam, Fawad; Mahmud, Hussain; Waheed, Abdul; Shakir, Murtaza; Afzal, Atif; Qayyum, Mohammad A.; Akram, Javed; Khan, Iqbal S.; Haque, Irshad U. // BMC Public Health;2005, Vol. 5 Issue 1, p124 

    Background: Knowledge about coronary heart disease (CHD) and its risk factors is an important pre-requisite for an individual to implement behavioral changes leading towards CHD prevention. There is scant data on the status of knowledge about CHD in the general population of Pakistan. The...

  • Established and Recently Identified Coronary Heart Disease Risk Factors in Young People: The Influence of Physical Activity and Physical Fitness. Thomas, Non Eleri; Baker, Julien S.; Davies, Bruce // Sports Medicine;2003, Vol. 33 Issue 9, p633 

    Epidemiological studies have identified several risk factors for coronary heart disease (CHD), many of which are present in young people. One such risk factor is hypertension. In adults, exercise is thought to have a positive effect on blood pressure levels; however, findings are inconclusive...

  • Diuretics and ALLHAT. Jackson, Graham // Update;7/10/2003, Vol. 67 Issue 3, p155 

    The article discusses implications of ALLHAT trial on the treatment of hypertensive patients. The ALLHAT trial addressed the question of superiority in preventing cardiovascular events comparing lisinopril, amlodipine, chlorthalidone and doxazosin in patients aged 55 years or older with...

  • Cardiovascular Drug Trial Discontinued.  // Applied Clinical Trials;Feb2011, Vol. 20 Issue 2, p14 

    The article reports that one of the two Phase III trials of Merck BioVentures' cardiovascular drug vorapaxar has been stopped by the Data Safety and Monitoring Board (DSMB). It mentions that the study has been conducted by Duke Clinical Research Institute wherein it included 13,000 subjects with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics